SCHEMBL4336060

SCHEMBL4336060

Cc1ccc(NC(=O)c2nc(CN3CCC(F)(F)CC3)c3ccccn23)nc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.68
CNR1 P21554 6/20 0.68
RAB9A P51151 5/20 0.42
NPC1 O15118 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
TP53 P04637 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPT P10636 2/20 0.40
HCRTR1 O43613 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334472 0.89 CNR2 (0.68) CNR2CNR1RAB9ANPC1SMN1; SMN2
SCHEMBL4333051 0.88 CNR1 (0.56) CNR2CNR1RAB9ANPC1SMN1; SMN2
SCHEMBL4333044 0.88 CNR1 (0.66) CNR2CNR1RAB9ANPC1SMN1; SMN2
SCHEMBL4324493 0.88 CNR2 (0.74) CNR2CNR1RAB9ANPC1METTL3
SCHEMBL4332318 0.87 CNR2 (0.66) CNR2CNR1RAB9ANPC1SMN1; SMN2
SCHEMBL4325110 0.87 CNR2 (0.73) CNR2CNR1RAB9ANPC1GAA
SCHEMBL4328565 0.86 CNR2 (0.65) CNR2CNR1KMT2AMEN1METTL3
SCHEMBL4336447 0.86 CNR2 (0.67) CNR2CNR1METTL3
SCHEMBL4328542 0.86 CNR2 (0.77) CNR2CNR1RAB9ANPC1SMN1; SMN2
SCHEMBL4468815 0.86 CNR2 (0.69) CNR2CNR1KDM4EALDH1A1METTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 CNR2 1/4885CNR1 2/4885RAB9A 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.